お探しの情報が見つかりませんでした
ホームページをご利用いただきありがとうございます。
誠に申し訳ございませんが、お探しの情報が見つかりませんでした。
お探しの情報は他の場所へ移動したか削除された可能性があります。
恐れ入りますがトップページもしくは下記コンテンツ一覧からお探しください。
コンテンツ一覧
- Structure, Mechanism of Action, KD Action
- Reduction of Toxicity
- Ligands for DDS
- Newly modified nucleic acids
- Japan Healthcare Venture Summit 2023
- Announcement on Completion of signing additional license agreement with Takeda Pharmaceutical Co., Ltd.
- Representative Director/CEO Mr.Toriya gave a lecture at the Symposium of the 143rd Annual Meeting of the Pharmaceutical Society of Japan on March 28, 2023
- Announcement on Completion of signing license agreement with NIPPON SHOKUBAI Co., Ltd..
- Announcement on Completion of signing license agreement with Nippon Gene Material Co., Ltd.
- Japan Healthcare Venture Summit 2022
- Notice of publication in the Nikkan Kogyo Shimbun
- Notice of publication in Nikkei Biotechnology
- Announcement on Completion of signing additional license agreement with Takeda Pharmaceutical Co., Ltd.
- Notice of publication in the magazine "NEW LEADER"
- Announcement of selection for an AMED drug discovery basic technology project for the realization of next-generation treatment and diagnosis entitled “Innovative Next Generation of Oligonucleotide Therapeutics (INGOT)”
- Japan Healthcare Venture Summit 2021
- Announcement on Completion of signing additional license agreement with Takeda Pharmaceutical Co., Ltd.
- Japan Healthcare Venture Summit 2020
- Notice of participation in Nippon Shokubai Group
- Notice of laboratory relocation
- Announcement on Completion of signing license agreement with Ionis Pharmaceuticals, Inc.
- Announcement on Completion of signing license agreement with Takeda Pharmaceutical Co., Ltd.
- BioJapan2018
- Past information